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ated with hypoxia, edema, or other 
unknown processes. However, the 
patient had no history of hypotensive 
episodes, hypoxemia, abnormal meta-
bolic and toxic processes, and other in-
fectious disease. In conclusion, IAAE 
with pandemic (H1N1) 2009 may be 
caused by direct viral infection of the 
CNS and, although its pathogenesis 
is not clear, physicians should remain 
alert to this possibility.
Song Mi Moon, Sung-Han Kim, 
Min Hee Jeong, Eun Hye Lee, 
and Tae-Sung Ko
Author afﬁ   liation: University of Ulsan Col-
lege of Medicine, Seoul, South Korea
DOI: 10.3201/eid1611.100682
References 
    1.   Kitcharoen S, Pattapongsin M, Sawan-
yawisuth K, Angela V, Tiamkao S. Neu-
rologic manifestations of pandemic 
(H1N1) 2009 virus infection. Emerg In-
fect Dis. 2010;16:569–70. DOI: 10.3201/
eid1603.091699
  2.   Kuiken  T,  Taubenberger  JK.  Pathol-
ogy of human inﬂ  uenza  revisited.  Vac-
cine. 2008;26(Suppl 4):D59–66. DOI: 
10.1016/j.vaccine.2008.07.025
  3.   Ito Y, Ichiyama T, Kimura H, Shibata M, 
Ishiwada N, Kuroki H, et al. Detection of 
inﬂ  uenza virus RNA by reverse transcrip-
tion PCR and proinﬂ  ammatory cytokines 
in inﬂ  uenza-virusassociated  encephal-
opathy. J Med Virol. 1999;58:420–5. 
DOI: 10.1002/(SICI)1096-9071(199908)
58:4<420::AID-JMV16>3.0.CO;2-T
  4.   Franková V, Jirásek A, Tumová B. Type 
A inﬂ  uenza: postmortem virus isolations 
from different organs in human lethal 
cases. Arch Virol. 1977;53:265–8. DOI: 
10.1007/BF01314671
  5.   Centers for Disease Control and Preven-
tion. Neurologic complications associ-
ated with novel inﬂ  uenza A (H1N1) virus 
infection in children, Dallas, Texas, May 
2009. MMWR Morb Mortal Wkly Rep. 
2009;58:773–8.
  6.   Gonzalez BE, Brust DG. Novel inﬂ  uenza 
A (H1N1) presenting as an acute febrile 
encephalopathy in a mother and daughter. 
Clin Infect Dis. 2009;49:1966–7. DOI: 
10.1086/649014
  7.   Webster RI, Hazelton B, Suleiman J, Mac-
artney K, Kesson A, Dale RC. Severe en-
cephalopathy with swine origin inﬂ  uenza 
A H1N1 infection in childhood: case re-
ports. Neurology. 2010;74:1077–8. DOI: 
10.1212/WNL.0b013e3181d6b113
  8.   Sánchez-Torrent  L,  Triviño-Rodriguez 
M, Suero-Toledano P, Claret-Teruel G, 
Muñoz-Almagro C, Martínez-Sánchez L, 
et al. Novel inﬂ  uenza A (H1N1) encepha-
litis in a 3-month-old infant. Infection. 
2010;38:227–9. DOI: 10.1007/s15010-
010-0014-3
    9.    Amin R, Ford-Jones E, Richardson SE, 
MacGregor D, Tellier R, Heurter H, et 
al. Acute childhood encephalitis and en-
cephalopathy associated with inﬂ  uenza: 
a prospective 11-year review. Pediatr In-
fect Dis J. 2008;27:390–5. DOI: 10.1097/
INF.0b013e31816507b2
10.   Ichiyama T, Isumi H, Ozawa H, Matsubara 
T, Morishima T, Furukawa S. Cerebrospi-
nal ﬂ  uid and serum levels of cytokines and 
soluble tumor necrosis factor receptor in 
inﬂ  uenza virus associated encephalopathy. 
Scand J Infect Dis. 2003;35:59–61. DOI: 
10.1080/0036554021000026986
Address for correspondence: Sung-Han Kim, 
Department of Infectious Diseases, Asan 
Medical Center, University of Ulsan College 
of Medicine, 388-1 Pungnap-2 dong, Songpa-
gu, Seoul 138-736, South Korea; email: 
kimsunghanmd@hotmail.com
Oseltamivir-
Resistant Pandemic 
(H1N1) 2009 
Treated with 
Nebulized Zanamivir 
To the Editor: In late November 
2009, a 3-year-old immunocompro-
mised boy experienced an upper respi-
ratory tract infection caused by inﬂ  u-
enza A pandemic (H1N1) 2009 virus, 
as demonstrated by a positive result for 
real-time PCR on a nasal swab speci-
men. His medical history was notable 
for a congenital intracardiac tumor; an 
ABO–incompatible heart transplant 
at 2 months of age; and an Epstein-
Barr virus–related humoral rejection 
20 months later that was treated with 
anti-CD20 and plasmapheresis and 
continuous immunosuppressive ther-
apy with tacrolimus and everolimus. 
Thus, a 5-day regimen of oseltamivir 
treatment was undertaken, and the pa-
tient’s clinical signs improved.
However, 3 days after drug treat-
ment was suspended, the child had a 
relapse and exhibited fever, cough, 
and mild respiratory distress. The 
patient had ﬁ  ne crackles in the left 
posterior basal lung, normal oxygen 
saturation, and an inﬁ   ltrate in the 
left basal lung, observed on chest 
radiograph. Infection with pandemic 
(H1N1) 2009 virus was conﬁ  rmed. 
He was then transferred to an isolated 
ward of the pediatric department, and 
oseltamivir treatment was again initi-
ated and dosages of immunosuppres-
sive drugs were reduced. However, 
no clinical or virologic responses 
were observed during the 3 weeks of 
drug administration.
Over the next month, the oral 
dosage of oseltamivir was increased 
twice, without substantial effects on 
clinical course and viral clearance 
of the infection (Figure). Because 
of persistence of infection, the viral 
neuraminidase gene was sequenced, 
which showed the H275Y mutation 
(1). We immediately requested zana-
mivir aqueous solution from GlaxoS-
mithKline (Brentford, UK), and, after 
the approval of the hospital’s ethics 
committee and parents’ consent were 
obtained, nebulized treatment was car-
ried out for 10 days. Fever and respira-
tory symptoms and signs resolved af-
ter 6 days of treatment and progressive 
real-time PCR gave negative results. 
Moreover, at the end of the treatment 
period, chest radiograph did not show 
abnormal ﬁ  ndings, and results of a he-
magglutination-inhibition assay were 
positive for inﬂ  uenza. No zanamivir-
related adverse events were observed, 
except for a mild bronchospasm that 
responded to albuterol.
Another notable point is that the 
clinical course of the disease was not 
severe, although the child was immu-
nocompromised and the infection per-
sisted for almost 2 months. However, 
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inﬂ   uenza virus persistence, possibly 
caused by inability of the child’s im-
mune system to clear the infection, 
and prolonged treatment with osel-
tamivir, led to the appearance of the 
H275Y mutation. H275Y has been de-
scribed as the most common mutation 
that confers oseltamivir resistance in 
pandemic (H1N1) 2009 infection and 
has been found in all the resistant iso-
lates reported worldwide (1). Consis-
tent with previous reports (2), in the 
patient described here, antiviral drug 
resistance arose early in the treatment 
course. Retrospective analysis dem-
onstrated the appearance of a mixed 
population after ≈2 weeks of drug use 
with a slow progression toward a pure 
H275Y variant. This latter ﬁ  nding may 
be explained by other virologic char-
acteristics of this viral isolate, which 
is currently undergoing deep sequenc-
ing of the full genome. 
Zanamivir represents the thera-
peutic option for patients infected 
with the H275Y mutation of pandemic 
(H1N1) 2009 virus. Its licensed for-
mulation as a dry powder is suitable 
only for patients who can actively use 
inhaled drugs and thus cannot be used 
in children <7 years of age (3). Intra-
venous zanamivir solution has been 
reported to be safe and effective in ex-
perimental inﬂ  uenza A virus infection 
and as compassionate therapy in 2 im-
munocompromised adult patients who 
underwent mechanical ventilation for 
severe pneumonia (4,5). Moreover, 
successful use of intravenous zana-
mivir in a critically ill child, who was 
immunosuppressed after allogenic 
stem cell transplantation and infected 
with oseltamivir-resistant pandemic 
(H1N1) 2009 virus, has been reported 
(6). In this latter case, the regimen was 
well tolerated and was associated with 
a decrease in viral load. 
Despite these results showing the 
efﬁ  cacy of zanamivir intravenous ad-
ministration, the inhalatory route for 
inﬂ  uenza virus–speciﬁ  c drugs should 
be the ﬁ   rst choice, whenever pos-
sible, because it delivers therapeutic 
molecules directly to the site of viral 
replication, resulting in low systemic 
exposure. For this reason and because 
of the mild severity of the patient’s 
disease, we decided to use zanamivir 
solution nebulized by aerosol. The 
compliance to this treatment was eas-
ily achieved, and the therapy showed 
good efﬁ  cacy and was well tolerated 
by the child. The minor side effect 
observed has already been reported in 
the literature (7). 
In conclusion, our experience 
supports the view that in immuno-
compromised patients with persistent 
infection, emergence of resistant viral 
strains should be strictly monitored. 
In this context, recently developed 
real-time PCRs for rapid screening of 
H275Y could be useful (8). Moreover, 
although a direct cause and effect has 
not been conﬁ  rmed, this case suggests 
that aerosolized zanamivir solution 
can be considered as a therapeutic op-
tion in young children with mild re-
spiratory symptoms who are infected 
with oseltamivir-resistant inﬂ  uenza 
viruses. Additional studies should 
be conducted in young patients with 
more severe disease.
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Figure. Schematic showing events surrounding oseltamivir-resistant pandemic (H1N1) 
2009 virus infection in 3-year-old immunocrompromised child, Italy, in relation to viremia 
levels, expressed as relative units of inﬂ   uenza A RNA, normalized with respect to the 
housekeeping gene RNaseP.LETTERS
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Enteric Viruses 
in Ready-to-Eat 
Packaged Leafy 
Greens
To the Editor: Fresh produce 
increasingly has been implicated in 
viral disease outbreaks (1). In some 
instances, lettuce was contaminated 
before wholesale distribution (1). En-
teric viruses can be introduced in the 
ﬁ  eld if produce is exposed to human 
waste. Processed and packaged pro-
duce can be contaminated if equip-
ment or wash water is not effectively 
sanitized. Fewer than 10 infectious 
viral particles are sufﬁ  cient to cause 
disease (2), and these organisms are 
resistant to disinfectants at concen-
trations that reduce bacterial levels 
(3). Contamination of fresh produce 
could pose a health risk to humans 
because fresh produce is eaten raw. 
High levels of viral contamination 
can result in large outbreaks, but 
intermittent contamination of fresh 
produce accounts for some sporad-
ic cases of norovirus and rotavirus 
gastroenteritis.
During April 27–November 23, 
2009, we performed viral testing on 
328 samples of packaged leafy greens 
(representing 12–14 different lots 
from 3–6 companies per week; no 
samples were taken on weeks with a 
statutory holiday) for norovirus or ro-
tavirus RNA. Packaged leafy greens 
were purchased from retail stores in 
southern Ontario, Canada. Shipments 
maintained an average temperature 
of 3.8°C during transit to the testing 
laboratory. Each 25-g sample was 
spiked with 106 PFU of feline calicivi-
rus (FCV) as a sample process control 
(4). Virus was concentrated by using 
an adsorption-elution-ultraﬁ  ltration 
ﬁ  ltration protocol (4).
Recovery of FCV was quantiﬁ  ed 
from an RNA standard curve. FCV 
process control recovery was <0.01% 
for 55 (17%) samples. Recovery of 
>0.01% of the FCV was observed for 
the remaining 273 (83%) samples. 
Two samples from which FCV was 
not recovered were positive for noro-
virus (CE-V-09–0138) and rotavirus 
(CE-V-09–0129); they were consid-
ered true positive results.
Of these 275 samples, 148 (54%) 
were positive for norovirus by real-
time reverse transcription–PCR (RT-
PCR) (5), and 1 (0.4%) was positive 
for rotavirus group A by RT-PCR (6). 
To conﬁ   rm detection of norovirus 
RNA, we ampliﬁ  ed a second norovi-
rus target by RT-PCR of region C (5). 
Only 40 samples (15% of total) pro-
duced a band of the expected size for 
this second norovirus amplicon. Of 
these 40 amplicons, only 16 (6% of to-
tal) could be sequenced to conﬁ  rm no-
rovirus RNA. The rotavirus-positive 
sample was conﬁ  rmed by sequencing.
For some sample dates, multiple 
lots were positive; for others, no posi-
tive samples were identiﬁ  ed (Figure). 
Multiple detections on the same date 
were not caused by cross-contamina-
tion; partial capsid sequencing showed 
different genetic types on dates when 
multiple samples were positive (Fig-
ure). Results were positive from 5 dif-
ferent brands, and no organic samples 
were conﬁ   rmed positive for enteric 
virus contamination. Of the 16 norovi-
rus strains conﬁ  rmed, 13 belonged to 
genogroup I (GI) and 3 to genogroup 
II (GII) (Figure). All were strain types 
known to be human pathogens. The 
group A rotavirus was not subtyped; 
group A rotaviruses can be human or 
animal pathogens.
Most noroviruses detected be-
longed to GI. Previous reports indicate 
that GI norovirus are more frequently 
identiﬁ  ed in foodborne or waterborne 
outbreaks; GII.4 noroviruses are more 
common in large outbreaks spread per-
son to person (7). Identiﬁ  cation of GI 
norovirus is consistent with occasional 
contamination of produce or wash wa-
ter. Disinfectants and sanitation agents 
are used in wash water at low concen-
trations, at which they have limited ef-
ﬁ  cacy against norovirus (3).
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, 
outbreaks, or original research are 
welcome. Letters commenting on ar-
ticles should contain no more than 
300 words and 5 references; they are 
more likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.